Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flibanserin - Sprout Pharmaceuticals

Next Previous
X
Search
Drug Profile

Flibanserin - Sprout Pharmaceuticals

Alternative Names: Addyi; BIMT 17; BIMT 17 BS; Girosa®

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Sprout Pharmaceuticals
  • Class Antidepressants; Anxiolytics; Benzimidazoles; Ketones; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Female sexual dysfunction
  • Discontinued Major depressive disorder

Most Recent Events

  • 16 Sep 2020 Launched for Female sexual dysfunction in Canada (PO)
  • 04 Sep 2019 Sprout Pharmaceuticals plans to change labelling elements for flibanserin under US FDA's Risk Evaluation and Mitigation Strategy programme
  • 12 Apr 2019 US FDA relaxes restrictions on alcohol use in women taking flibanserin for treatment of Female sexual dysfunction

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top